Rapid Identification of Antibiotic Resistance

Thousands of people die each year from hospital acquired infections (HAI) caused by antibiotic-resistant bacteria. Physicians could treat most infections successfully – even those caused by “superbugs” – if they could identify antibiotic resistance within a few hours of symptom onset. But bacterial culture usually takes one to three days – far too late to guide antibiotic therapy.

Our mission: to deliver bacterial identification and specific antibiotic susceptibility testing within 8 hours of specimen receipt. We're developing the BACcel™ system, a new analytical system that eliminates culturing to provide same-day results.

News: Accelr8 Announces Collaboration with Denver Health Medical Center in Study of ICU Patients ... read more

News: Study Results with Rapid ESBL Test for Broad Resistance in Gram-Negative Pathogens ... read more

News: Study Results Project the Impact of Rapid Diagnosis on Choice of Initial Therapy in Serious Infections ... read more

News: Accelr8 Announces New Results on OptiChem® Scalable Manufacturing Methods for Advanced Biomedical Applications ... read more

News: Accelr8 Announces Independent Study Presentations and New Rapid ESBL Test ... read more

Related News: New Yorker article by Dr. Jerome Groopman, an excellent big-picture review of all of the emerging types of "superbugs" and the related medical issues. Printable link (free) ...

New Information: Journal publication describes photolithographic production of OptiChem® patterns for specific cell attachment and growth ... read more

News: Accelr8 Presents Research Results on Direct Bacterial Extraction and “Superbug” Tests ... read more

News: Accelr8 and BD Sign Research and Licensing Option Agreement for Commercializing Accelr8's BACcel™ Rapid Diagnostics Technology ... read more

News: Accelr8 Announces Research Programs in Two Leading Medical Research Centers ... read more

New Information: IDSA Public Policy Statement (free PDF download) The Epidemic of Antibiotic-Resistant Infections (in Clinical Infectious Diseases, Jan 15, 2008)

News: BD Acquires Right to Negotiate Business Relationship for Accelr8's BACcel® Rapid Diagnostics Technology ... read more

News: Accelr8 Announces Sale of Two New Licenses for OptiChem® Surface Coatings ... read more

New Information: BACcel® System Backgrounder and BACcel® Q&A.

Learn more about Antibiotic Resistance and The BACcel®	Company Reports	Web Site Updates